Fig. 1: Immunisation of mice with NiV sG, ChAdOx1 NiV G or NiV mcsF induces varied antibody and T-cell responses.
From: Nipah virus vaccines evaluated in pigs as a ‘One Health’ approach to protect public health
Mice were immunised on day 0 and 21 by intramuscular inoculation of 5 µg NiV sG, NiV mcsF, or HeV sG proteins in adjuvant, or 1 × 108 IU ChAdOx1 NiV G. A NiV mcsF and sG binding antibody titres (EPT) in serum on day 21 and 42; B Virus neutralising titres in day 21 and 42 serum as assessed by NiVM VNT; C, D CD8+ and CD4+ T-cell cytokine responses after stimulation of splenocytes with NiV G peptides, respectively; E, F CD8+ and CD4+ T-cell cytokine responses after stimulation of splenocytes with NiV F peptides, respectively. Splenocytes from all groups were restimulated with NiV G peptides, whereas splenocytes from the NiV sG, NiV mcsF and adjuvant only groups were restimulated with NiV F peptides. Datapoints represent individual mice, with the bars showing the group mean and error bars represent the standard deviation (SD). Significant differences were determined using two-way ANOVA and signified with the following letter: a—significant difference to adjuvant; b—significant difference to NiV sG; c—significant difference to ChAdOx1 NiV G; d—significant difference to NiV mcsF; e—significant difference to HeV sG.
